IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq: ELGX) announces that enrollment is complete in its multicenter, nonrandomized, controlled IDE clinical trial that is intended to support U.S. Food and Drug Administration (FDA) approval of the large 34 mm diameter Powerlink® infrarenal cuff in conjunction with the Powerlink bifurcated stent graft system. Patients will continue to be followed to complete the one year primary endpoint analysis, during which time an additional 120 patients may be treated and followed at up to 20 clinical sites under an FDA-approved continued access provision of this protocol.
